Grey Wolf Raises $49m To Bring ‘Tumor Unmasking’ Candidate To Clinic
Series B Financing Oversubscribed
The UK biotech will use the funds to advance the development of its first-in-class ERAP1 inhibitor, which could circumvent the limitations of poor tumor visibility and T cell exhaustion.
